AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23989837
Drug: Resin infiltration
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin infiltration treatment for WSLs
Trial: 18507832
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and Omeprazole (OA)
Trial: 18507832
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with OA and CLR (OAC)
Trial: 17073704
Drug: Prostanoids (e.g.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostanoids (e.g., PGE(1)) used for treatment of peripheral arterial disease
Trial: 14621749
Drug: Vasodilator drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasodilator drugs during organ procurement
Trial: 26564102
Drug: Cerebrolysin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (30 mL/d) for 21 days
Trial: 20508185
Drug: Recreational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational therapy (playing cards, bingo, or 'Jenga')
Trial: 16873669
Drug: R-CHOP induction
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP induction (R: 375 mg/m² intravenously, day 1)
Trial: 16873669
Drug: R maintenance
RxNorm normalized name: urinary catheter maintenance solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R maintenance (375 mg/m² intravenously once every 3 months for a maximum of 2 years)
Trial: 14608138
Drug: In-hospital initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In-hospital initiation of cardiovascular protective medications (including antiplatelet therapy, beta-blockers, ACE inhibitors, and lipid-lowering therapy)
Trial: 1634926
Drug: Thiotepa (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiotepa (75 mg/m2) + GM-CSF (10 micrograms/kg)
Trial: 1634926
Drug: Thiotepa (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiotepa (75 mg/m2) + GM-CSF (5 micrograms/kg)
Trial: 1634926
Drug: Thiotepa (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiotepa (75 mg/m2) + GM-CSF (10 or 5 micrograms/kg)
Trial: 25370364
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy for Obesity (CRT‐O)
Trial: 12740277
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (no BPS)
Trial: 3468598
Drug: Effervescent vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent vitamin C preparations
Trial: 3468598
Drug: Effervescent calcium
RxNorm normalized name: Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent calcium preparations
Trial: 3468598
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C preparations (excess consumption)
Trial: 29943185
Drug: Immediate post-treatment
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Immediate post-treatment non-perfused volume (NPV)
Trial: 21747837
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulfate (10 mg/kg/day for 45 days)
Trial: 21747837
Drug: Systemic meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic meglumine antimoniate (20 mg/kg/day intramuscularly for 20 days)
Trial: 17250728
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mirtazapine 4.5 mg and ibuprofen 400 mg
Trial: 17250728
Drug: Mirtazapine 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 4.5 mg
Trial: 15899956
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment 25.0 microg/kg.d
Trial: 15899956
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment 12.5 microg/kg.d
Trial: 10321443
Drug: Indapamide 1.25
RxNorm normalized name: indapamide 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 1.25 mg daily
Trial: 10321443
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of indapamide and low-salt diet
Trial: 2197755
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment for hyperlipidemia
Trial: 2197755
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for hyperlipidemia
Trial: 2197755
Drug: Combined therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapies for hyperlipidemia
Trial: 403549
Drug: Marijuana (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana (500 mg cigarette containing 2.1% delta9-THC)
Trial: 31702120
Drug: ACBMNC infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACBMNC infusion (5 × 10^7 cells/kg)
Trial: 24069775
Drug: Shortened postpartum
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shortened postpartum course of magnesium sulphate (two doses of intramuscular magnesium sulphate given four hours apart)
Trial: 19891687
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% foam applied twice daily for up to 2 weeks on psoriatic skin
Trial: 19891687
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% foam applied once daily for up to 4 weeks on psoriatic skin
Trial: 19891687
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% foam applied once daily for 4 weeks on healthy skin
Trial: 14687248
Drug: Amoxicillin 875
RxNorm normalized name: amoxicillin 875 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 875 mg plus clavulanic acid 125 mg b.i.d., clarithromycin 500 mg b.i.d., omeprazole 20 mg b.i.d. (ACCO)
Trial: 9562690
Drug: Engerix-B (commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix-B (commercial vaccine)
Trial: 2738328
Drug: Cefotetan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (2 gr single dose during operation)
Trial: 23029946
Drug: Flupirtine maleate
RxNorm normalized name: flupirtine maleate
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine maleate 100 mg thrice daily
Trial: 23029946
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride 50 mg thrice daily
Trial: 20491044
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab (1.25 mg) 48 hours before surgery
Trial: 20491044
Drug: No intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravitreal injection (control group)
Trial: 16082697
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nebulized albuterol
Trial: 16082697
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nebulized racemic epinephrine
Trial: 10402146
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment response (week 2)
Trial: 2304505
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of Edmonston-Zagreb vaccine
Trial: 2304505
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose of Edmonston-Zagreb vaccine
Trial: 2304505
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of Edmonston-Zagreb vaccine
Trial: 2304505
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of Schwarz vaccine
Trial: 2304505
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose of Schwarz vaccine
Trial: 2304505
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of Schwarz vaccine
Trial: 2304505
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of Schwarz vaccine in nine-month-olds
Trial: 7202858
Drug: Myo-inositol tablets
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myo-inositol tablets
Trial: 24252125
Drug: Patient-level intervention
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-level intervention (one-hour visit with a Prevention Practitioner providing a tailored 'prevention prescription')
Trial: 19250820
Drug: Post-radiation ('maintenance')
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-radiation ('maintenance') chemotherapy
Trial: 19250820
Drug: Pre-radiation ('sandwich')
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-radiation ('sandwich') chemotherapy
Trial: 17503220
Drug: Supportive-expressive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive group therapy (SEGT)
Trial: 1801560
Drug: Intravenous gamma-globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gamma-globulin (IVGG) at doses of 200 or 400 mg/kg X 5
Trial: 1801560
Drug: Intravenous gamma-globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gamma-globulin (IVGG)
Trial: 26381519
Drug: Intravenous rhAPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rhAPC (24 µg·kg(‐1)·h(‐1))
Trial: 23085041
Drug: 14-week behavioral
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-week behavioral treatment
Trial: 31425781
Drug: Mepolizumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab treatment
Trial: 9017772
Drug: Ceftibuten (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten (400 mg)
Trial: 9017772
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (500 mg)
Trial: 9017772
Drug: Cefaclor (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (500 mg)
Trial: 3531311
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg b.i.d. plus aspirin 650 mg q.i.d.
Trial: 3531311
Drug: Placebo b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo b.i.d. plus aspirin 650 mg q.i.d.
Trial: 28481230
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g isomaltulose in 400 mL of water
Trial: 28481230
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g isomaltulose in 400 mL of green tea
Trial: 28481230
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g sucrose in 400 mL of water
Trial: 16571280
Drug: Astragalus Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus Injection (AI) 20 ml in 250 ml of 5% glucose solution given through intravenous dripping
Trial: 12775739
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa plus low-dose cytarabine (IFN+LDAC)
Trial: 10367553
Drug: MDMA (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.7 mg/kg, orally) in humans
Trial: 10367553
Drug: MDMA (1.7,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.7, 5.4, and 17.0 mg/kg) in rats
Trial: 8904739
Drug: Befloxatone 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befloxatone 2.5 mg
Trial: 1653145
Drug: Controlled-release tablets
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release tablets (30 mg every 12 h)
Trial: 1653145
Drug: Solution (15
RxNorm normalized name: carboxymethylcellulose sodium 0.5 % Ophthalmic Solution (15 mL) / mineral oil 42.5 % / petrolatum 57.3 % Ophthalmic Ointment (3.5 GM) Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution (15 mg every 6 h)
Trial: 27434297
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Nilotinib
Trial: 27434297
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Nilotinib
Trial: 17690742
Drug: FEXOFENADINE 180
RxNorm normalized name: fexofenadine 180 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEXOFENADINE 180 mg Film Tablet (Drogsan A.S., Ankara, Turkey)
Trial: 17690742
Drug: Telfast 180
RxNorm normalized name: WORMWOOD 55.8 g in 60 mL TOPICAL LIQUID [Healfast]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telfast 180 mg Tablet (Aventis Pharma, Frankfurt am Main, Germany)
Trial: 40893
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose norgestrel/ethinyl estradiol preparation (300 mcg norgestrel and 30 mcg ee)
Trial: 29659183
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intravitreal aflibercept (IVT‐AFL) injection every 4 weeks (0.5q4)
Trial: 29659183
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg IVT‐AFL every 4 weeks (2q4)
Trial: 29659183
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg IVT‐AFL every 8 weeks (2q8)
Trial: 29659183
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intravitreal ranibizumab every 4 weeks (0.5q4)
Trial: 29659183
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (IVT‐AFL and ranibizumab)
Trial: 18091548
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin G 10% (ivIgG) - 6 mL [600 mg]/kg on day 1 and 3 mL [300 mg]/kg on day 2
Trial: 18091548
Drug: Placebo (albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (albumin 0.1%) - 6 mL [6 mg]/kg on day 1 and 3 mL [3 mg]/kg on day 2
Trial: 18091548
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin G 10% (ivIgG)
Trial: 16935946
Drug: Telephone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone administered cognitive behaviour therapy (CBT)
Trial: 21929831
Drug: Face to
RxNorm normalized name: NAIR FACE TOP CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face to face cognitive behaviour therapy (CBT)
Trial: 12971668
Drug: Family-based directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based directly observed treatment (FDOT)
Trial: 12971668
Drug: Standard supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard supervised but non-observed therapy (ST)
Trial: 3302841
Drug: Trazodone hydrochloride
RxNorm normalized name: Trazodone Hydrochloride
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trazodone hydrochloride 150 mg/day
Trial: 2190839
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg tamoxifen/day
Trial: 2190839
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg tamoxifen/day and 600 IU kallikrein/day
Trial: 31520695
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy followed by resectability assessment by the Expert Panel
Trial: 23443875
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol (1,000 mg)
Trial: 23443875
Drug: Intracutaneous sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous sterile water injection
Trial: 14679399
Drug: 3MU of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3MU of IFN-beta twice a day at intervals of 5 and 19 h (Group A)
Trial: 14679399
Drug: 3MU of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3MU of IFN-beta twice a day at intervals of 10 and 14 h (Group B)
Trial: 10655829
Drug: Sequential single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential single pumping regimen
Trial: 2069370
Drug: Netilmicin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin (6 mg/kg/day) given once daily (qd)
Trial: 2069370
Drug: Netilmicin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin (6 mg/kg/day) given thrice daily (tid)
Trial: 6347782
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg three times a day for 4-6 weeks
Trial: 25750093
Drug: Mud-bath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud-bath therapy (MBT)
Trial: 23403431
Drug: GSK1322322 (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 (100, 200, 400, 800, 1500 mg; 800 mg with high-fat meal)
Trial: 23403431
Drug: GSK1322322 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 (800 mg with high-fat meal)
Trial: 19754931
Drug: Proprietary melon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary melon juice concentrate (Extramel) 10 mg corresponding to 140 IU SOD per capsule, taken once daily for 4 weeks
Trial: 19754931
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken once daily for 4 weeks
Trial: 1389351
Drug: Rembrandt Lightening
RxNorm normalized name: Rembrandt
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rembrandt Lightening Gel and Whitening Toothpaste
Trial: 3905327
Drug: Iso Mack
RxNorm normalized name: iso-sulfan blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iso Mack Retard 20 mg
Trial: 3905327
Drug: Isoket Retard
RxNorm normalized name: Isoket Retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoket Retard 20 mg
Trial: 3905327
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release preparations
Trial: 3905327
Drug: Isoket retard
RxNorm normalized name: Isoket Retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoket retard 20 mg
Trial: 29670335
Drug: Fimasartan (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan (120 mg)
Trial: 20150523
Drug: Rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (20 mg)
Trial: 29670335
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of fimasartan and rosuvastatin
Trial: 25171881
Drug: Magnetic sphincter
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic sphincter augmentation (MSAD)
Trial: 21192940
Drug: Oral progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral progesterone (150 mg BID) during the follicular phase
Trial: 18492838
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of phytosterols and (n‐3) LCPUFA
Trial: 16538000
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (INS group)
Trial: 14618042
Drug: Intravenous esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esmolol for 24 hours post-CABG followed by oral beta-blocker
Trial: 14618042
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral beta-blocker treatment
Trial: 8325278
Drug: Oral flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral flumazenil (30 or 100 mg)
Trial: 3791364
Drug: tolciclate solution
RxNorm normalized name: tolciclate
DrugBank: Tolciclate (DB13360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolciclate solution